Literature DB >> 29525493

Riluzole, disease stage and survival in ALS.

Thanuja Dharmadasa1, Matthew C Kiernan2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29525493     DOI： 10.1016/S1474-4422(18)30091-7

Source DB:  PubMed          Journal:  Lancet Neurol        ISSN： 1474-4422            Impact factor:   44.182


× No keyword cloud information.
  16 in total

1.  Critical Care Management of Acute Spinal Cord Injury-Part II: Intensive Care to Rehabilitation.

Authors:  Amanda Sacino; Kathryn Rosenblatt
Journal:  J Neuroanaesth Crit Care       Date:  2019-09-13

2.  Selective C9orf72 G-Quadruplex-Binding Small Molecules Ameliorate Pathological Signatures of ALS/FTD Models.

Authors:  Aifang Cheng; Changdong Liu; Wenkang Ye; Duli Huang; Weiyi She; Xin Liu; Chun Po Fung; Naining Xu; Monica Ching Suen; Wei Ye; Herman Ho Yung Sung; Ian Duncan Williams; Guang Zhu; Pei-Yuan Qian
Journal:  J Med Chem       Date:  2022-09-15       Impact factor: 8.039

3.  Prevalence of amyotrophic lateral sclerosis in the United States using established and novel methodologies, 2017.

Authors:  Paul Mehta; Jaime Raymond; Reshma Punjani; Moon Han; Theodore Larson; Wendy Kaye; Lorene M Nelson; Barbara Topol; Oleg Muravov; Corina Genson; D Kevin Horton
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2022-04-15       Impact factor: 3.528

Review 4.  From Riluzole to Dexpramipexole via Substituted-Benzothiazole Derivatives for Amyotrophic Lateral Sclerosis Disease Treatment: Case Studies.

Authors:  Serge Mignani; Jean-Pierre Majoral; Jean-François Desaphy; Giovanni Lentini
Journal:  Molecules       Date:  2020-07-22       Impact factor: 4.411

5.  Prevalence of Amyotrophic Lateral Sclerosis - United States, 2015.

Authors:  Paul Mehta; Wendy Kaye; Jaime Raymond; Reshma Punjani; Theodore Larson; Jessica Cohen; Oleg Muravov; Kevin Horton
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2018-11-23       Impact factor: 17.586

6.  Rethinking to riluzole mechanism of action: the molecular link among protein kinase CK1δ activity, TDP-43 phosphorylation, and amyotrophic lateral sclerosis pharmacological treatment.

Authors:  Maicol Bissaro; Stefano Moro
Journal:  Neural Regen Res       Date:  2019-12       Impact factor: 5.135

Review 7.  Neuroimmune crosstalk and evolving pharmacotherapies in neurodegenerative diseases.

Authors:  Falguni Baidya; Mariya Bohra; Aishika Datta; Deepaneeta Sarmah; Birva Shah; Priya Jagtap; Swapnil Raut; Ankan Sarkar; Upasna Singh; Kiran Kalia; Anupom Borah; Xin Wang; Kunjan R Dave; Dileep R Yavagal; Pallab Bhattacharya
Journal:  Immunology       Date:  2020-10-06       Impact factor: 7.397

Review 8.  Targeting Two-Pore Channels: Current Progress and Future Challenges.

Authors:  Xuhui Jin; Yuxuan Zhang; Abeer Alharbi; Ali Hanbashi; Ali Alhoshani; John Parrington
Journal:  Trends Pharmacol Sci       Date:  2020-08       Impact factor: 14.819

9.  Intravenously Administered, Retinoid Activating Nanoparticles Increase Lifespan and Reduce Neurodegeneration in the SOD1G93A Mouse Model of ALS.

Authors:  David X Medina; Eugene P Chung; Collin D Teague; Robert Bowser; Rachael W Sirianni
Journal:  Front Bioeng Biotechnol       Date:  2020-03-27

Review 10.  From basic research to the clinic: innovative therapies for ALS and FTD in the pipeline.

Authors:  Rajka Maria Liscic; Antonella Alberici; Nigel John Cairns; Maurizio Romano; Emanuele Buratti
Journal:  Mol Neurodegener       Date:  2020-06-01       Impact factor: 14.195
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.